Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Erlotinib (Tarceva) in Routine Clinical Practice for First Line Maintenance Therapy (1LM) in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)

NCT01194050 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01194050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01194050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Erlotinib (Tarceva) in Routine Clinical Practice for First Line Maintenance Therapy (1LM) in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
June 30, 2010
Completion date
July 31, 2013
Enrollment
289 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer